We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Masimo (MASI) Right Now
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) is currently one of the top-performing stocks in the MedTech space. The company’s strong fundamentals and global expansion are major positives at the moment.
Shares Up
In the past year, Masimo’s shares have rallied 7.8% against the industry’s decline of 2.5%.
The Zacks Rank #2 (Buy) stock currently has a Growth Score of A. This reflects possibilities of outperformance over the long haul. Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or #2 are better picks than most.
In the last 60 days, the Zacks Consensus Estimate for Masimo’s current-year earnings per share rose 1% to $2.89.
Furthermore, in the last reported quarter, Masimo secured a substantial contract for its Rad-67 with blood transfusion centers in Valencia, Spain.
Raised Guidance
For 2018, revenues are estimated at $846 million, up from the previous projection of $836 million. The Zacks Consensus Estimate is pegged at $843.8 million, below the guided figure.
Adjusted earnings per share for 2018 are expected at $2.88, up from the previous guidance of $2.80. The Zacks Consensus Estimate is pinned at $2.89, slightly above the projected figure.
Other Key Picks
Some other top-ranked medical stocks are Genomic Health , Stryker Corporation (SYK - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank #2.
Integer Holdings a long-term expected earnings growth rate of 15%. The stock carries a Zacks Rank #2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Here's Why You Should Invest in Masimo (MASI) Right Now
Masimo Corporation (MASI - Free Report) is currently one of the top-performing stocks in the MedTech space. The company’s strong fundamentals and global expansion are major positives at the moment.
Shares Up
In the past year, Masimo’s shares have rallied 7.8% against the industry’s decline of 2.5%.
The Zacks Rank #2 (Buy) stock currently has a Growth Score of A. This reflects possibilities of outperformance over the long haul. Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or #2 are better picks than most.
In the last 60 days, the Zacks Consensus Estimate for Masimo’s current-year earnings per share rose 1% to $2.89.
Masimo Corporation Price and Consensus
Masimo Corporation Price and Consensus | Masimo Corporation Quote
Let’s find out whether the bullish trend can sustain the stock’s impressive performance in the long run.
What Makes It an Attractive Pick?
Fundamental Growth Story
Masimo has been gaining from its strong fundamentals.
Since 2009, the company’s revenues grew to $798 million, at a CAGR of 10.9%.
Furthermore, Masimo’s earnings saw a CAGR of 15.5% to $2.82 since 2009.
Global Exposure
Masimo has significant international presence.
The California-based company’s flagship Eve application has been recently picked by the UAE Ministry of Health & Prevention (MOHAP). (Read more: MOHAP Selects Masimo's Eve for CCHD Screening in UAE)
Earlier this year, Masimo’s technologies were implemented by NU Hospitals, a Bangalore-based nephrology care center in India. (Read more: Masimo Products to Boost India-Based NU Hospitals' Systems)
Furthermore, in the last reported quarter, Masimo secured a substantial contract for its Rad-67 with blood transfusion centers in Valencia, Spain.
Raised Guidance
For 2018, revenues are estimated at $846 million, up from the previous projection of $836 million. The Zacks Consensus Estimate is pegged at $843.8 million, below the guided figure.
Adjusted earnings per share for 2018 are expected at $2.88, up from the previous guidance of $2.80. The Zacks Consensus Estimate is pinned at $2.89, slightly above the projected figure.
Other Key Picks
Some other top-ranked medical stocks are Genomic Health , Stryker Corporation (SYK - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
Genomic Health has an expected earnings growth rate of 187.5%. The stock flaunts a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank #2.
Integer Holdings a long-term expected earnings growth rate of 15%. The stock carries a Zacks Rank #2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>